News in Numbers

Bladder cancer diagnoses are set to climb to over 300,000 in by 2033 in the eight major markets, with men and over-60s most at risk, according to a new report by GlobalData.

GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.

Pfizer has reported a 30% year over year increase in revenues in Q3 2024 compared to last year largely due to sales from the company’s Covid-19 drugs Paxlovid and Comirnaty.

Eisai has lowered its revenue forecast for Q2 2024 for its Alzheimer’s drug Leqembi (lecanemab) to $280m from $370m, primarily citing delays in revenue in the US.

Canadian biotech Aurinia Pharmaceuticals has announced it will be axing its workforce by 45% in a major restructuring plan aimed at streamlining operations.